Role of the tumor microenvironment in PD-L1/PD-1-mediated tumor immune escape

Role of the tumor microenvironment in PD-L1/PD-1-mediated tumor immune escape

Abstract Tumor immune escape is an important strategy of tumor survival. There are many mechanisms of tumor immune escape, including immunosuppression, which has become a research hotspot in recent years. The programmed death ligand-1/programmed death-1 (PD-L1/PD-1) signaling pathway is an important...

Full description

Bibliographic Details
Main Authors:	Xianjie Jiang, Jie Wang, Xiangying Deng, Fang Xiong, Junshang Ge, Bo Xiang, Xu Wu, Jian Ma, Ming Zhou, Xiaoling Li, Yong Li, Guiyuan Li, Wei Xiong, Can Guo, Zhaoyang Zeng
Format:	Article
Language:	English
Published:	BMC 2019-01-01
Series:	Molecular Cancer
Subjects:	Tumor immune escape PD-L1 PD-1 Tumor microenvironment Inflammatory factor
Online Access:	http://link.springer.com/article/10.1186/s12943-018-0928-4

Similar Items

Exosomal PD-L1: New Insights Into Tumor Immune Escape Mechanisms and Therapeutic Strategies
by: Kaijian Zhou, et al.
Published: (2020-10-01)

PD-1/PD-L1 Checkpoint Inhibitors in Tumor Immunotherapy
by: Jinhua Liu, et al.
Published: (2021-09-01)

Advances of PD-1/PD-L1 Inhibitors in Tumor Immunotherapy
by: Yong-jun LIU, et al.
Published: (2017-06-01)

PD-1 and PD-L1 expression in pulmonary carcinoid tumors and their association to tumor spread
by: Tiina Vesterinen, et al.
Published: (2019-08-01)

Immunosuppression in Gliomas via PD-1/PD-L1 Axis and Adenosine Pathway
by: Thamiris Becker Scheffel, et al.
Published: (2021-02-01)

Prognostic value of PD-L1 and PD-1 expression in pulmonary neuroendocrine tumors
by: Fan Y, et al.
Published: (2016-10-01)

PD-L1 Immunohistochemical Detection in Tumor Cells and Tumor Microenvironment: Main Considerations on the Use of Tissue Micro Arrays
by: Gerardo Botti, et al.
Published: (2016-06-01)

The combination of anti-KIR monoclonal antibodies with anti-PD-1/PD-L1 monoclonal antibodies could be a critical breakthrough in overcoming tumor immune escape in NSCLC
by: He YY, et al.
Published: (2018-04-01)

PD-L1 and PD-L2 expression in the tumor microenvironment including peritumoral tissue in primary central nervous system lymphoma
by: Motomasa Furuse, et al.
Published: (2020-04-01)

PD-1/PD-L1 Blockade Therapy for Tumors with Downregulated MHC Class I Expression
by: Michal Šmahel
Published: (2017-06-01)

A Novel PD-L1-targeting Antagonistic DNA Aptamer With Antitumor Effects
by: Wei-Yun Lai, et al.
Published: (2016-01-01)

Atovaquone-HSA nano-drugs enhance the efficacy of PD-1 blockade immunotherapy by alleviating hypoxic tumor microenvironment
by: Simeng Wang, et al.
Published: (2021-10-01)

PD-L1 and PD-1 and characterization of tumor-infiltrating lymphocytes in high grade sarcomas of soft tissue – prognostic implications and rationale for immunotherapy
by: Melanie Boxberg, et al.
Published: (2018-03-01)

The role of exosomal PD-L1 in tumor progression and immunotherapy
by: Feiting Xie, et al.
Published: (2019-10-01)

Targeted Glucose or Glutamine Metabolic Therapy Combined With PD-1/PD-L1 Checkpoint Blockade Immunotherapy for the Treatment of Tumors - Mechanisms and Strategies
by: Guofeng Ma, et al.
Published: (2021-07-01)

PD-L1 Expression is Highly Associated with Tumor-Associated Macrophage Infiltration in Nasopharyngeal Carcinoma
by: Deng R, et al.
Published: (2020-11-01)

Targeting CXCR4 potentiates anti-PD-1 efficacy modifying the tumor microenvironment and inhibiting neoplastic PD-1
by: Crescenzo D’Alterio, et al.
Published: (2019-10-01)

PD-L1-Mediated Immunosuppression in Glioblastoma Is Associated With the Infiltration and M2-Polarization of Tumor-Associated Macrophages
by: Zhiyuan Zhu, et al.
Published: (2020-11-01)

Spatial and Temporal Changes in PD-L1 Expression in Cancer: The Role of Genetic Drivers, Tumor Microenvironment and Resistance to Therapy
by: Elena Shklovskaya, et al.
Published: (2020-09-01)

Determination of PD-L1 Expression in Circulating Tumor Cells of NSCLC Patients and Correlation with Response to PD-1/PD-L1 Inhibitors
by: Melanie Janning, et al.
Published: (2019-06-01)

PD-L1 and CD4 are independent prognostic factors for overall survival in endometrial carcinomas
by: Shuang Zhang, et al.
Published: (2020-02-01)

Tumor-infiltrating T cells and PD-L1 expression in childhood malignant extracranial germ-cell tumors
by: Renata Boldrini, et al.
Published: (2019-02-01)

The Periphery of Salivary Gland Carcinoma Tumors Reveals a PD-L1/PD-1 Biomarker Niche for the Evaluation of Disease Severity and Tumor—Immune System Interplay
by: Martin Kuchar, et al.
Published: (2021-01-01)

Increased SNX20 and PD-L1 Levels Can Predict the Clinical Response to PD-1 Inhibitors in Lung Adenocarcinoma
by: Fan L, et al.
Published: (2020-10-01)

The construction, expression, and enhanced anti-tumor activity of YM101: a bispecific antibody simultaneously targeting TGF-β and PD-L1
by: Ming Yi, et al.
Published: (2021-02-01)

Single-cell transcriptomics reveals the effect of PD-L1/TGF-β blockade on the tumor microenvironment
by: Yoong Wearn Lim, et al.
Published: (2021-05-01)

Drug response to PD-1/PD-L1 blockade: based on biomarkers
by: Chen Q, et al.
Published: (2018-08-01)

Preclinical Rationale for Targeting the PD-1/PD-L1 Axis in Combination with a CD38 Antibody in Multiple Myeloma and Other CD38-Positive Malignancies
by: Christie P. M. Verkleij, et al.
Published: (2020-12-01)

A novel MDSC-induced PD-1−PD-L1+ B-cell subset in breast tumor microenvironment possesses immuno-suppressive properties
by: Meng Shen, et al.
Published: (2018-04-01)

Systematic Assessment of Risk of Fever in Solid Tumor Patients Treated With PD-1/PD-L1 Inhibitors: A Systematic Review and Meta-Analysis
by: Hongmei Liu, et al.
Published: (2020-10-01)

Molecular heterogeneity of anti-PD-1/PD-L1 immunotherapy efficacy is correlated with tumor immune microenvironment in East Asian patients with non-small cell lung cancer
by: Runsen Jin, et al.
Published: (2020-08-01)

Mechanisms regulating PD-L1 expression on tumor and immune cells
by: Shuming Chen, et al.
Published: (2019-11-01)

Regulation of Immunity in Clear Cell Renal Carcinoma: Role of PD-1, PD-L1, and PD-L2
by: Liudmila Spirina, et al.
Published: (2021-09-01)

MiR-195/-16 Family Enhances Radiotherapy via T Cell Activation in the Tumor Microenvironment by Blocking the PD-L1 Immune Checkpoint
by: Zhen Tao, et al.
Published: (2018-07-01)

PD-L1/PD-1 Axis in Multiple Myeloma Microenvironment and a Possible Link with CD38-Mediated Immune-Suppression
by: Federica Costa, et al.
Published: (2021-01-01)

Regulation of PD-L1 expression in the tumor microenvironment
by: Ming Yi, et al.
Published: (2021-01-01)

PD-L1 expression in the microenvironment and the response to checkpoint inhibitors in head and neck squamous cell carcinoma
by: D. Evrard, et al.
Published: (2020-01-01)

Sanguisorbae Radix Suppresses Colorectal Tumor Growth Through PD-1/PD-L1 Blockade and Synergistic Effect With Pembrolizumab in a Humanized PD-L1-Expressing Colorectal Cancer Mouse Model
by: Eun-Ji Lee, et al.
Published: (2021-09-01)

M1-like TAMs are required for the efficacy of PD-L1/PD-1 blockades in gastric cancer
by: Rui Zhao, et al.
Published: (2021-01-01)

Association Between Tumor Mutation Burden (TMB) and Outcomes of Cancer Patients Treated With PD-1/PD-L1 Inhibitions: A Meta-Analysis
by: Jiaxin Zhu, et al.
Published: (2019-06-01)